Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2016 11:05 ET | Source: Genmab A/S

Genmabs samlede antal stemmerettigheder og samlede aktiekapital

Selskabsmeddelelse Offentliggørelse af stemmerettigheder og aktiekapital København, Danmark, 31. august 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) skal i henhold til § 10 i...
August 31, 2016 11:05 ET | Source: Genmab A/S

Genmab’s Total Number of Voting Rights and Total Share Capital

Company Announcement Publication of voting rights and share capital Copenhagen, Denmark; August 31, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announces that pursuant to section 10 of...
August 31, 2016 05:09 ET | Source: Genmab A/S

Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

Company Announcement Arzerra now approved by U.S. FDA for use in combination with fludarabine and cyclophosphamide in relapsed CLL Approval based on data from Phase III COMPLEMENT 2...
August 31, 2016 05:09 ET | Source: Genmab A/S

Genmab meddeler, at de amerikanske sundhedsmyndigheder (FDA) har godkendt Arzerra® (ofatumumab) i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL

Selskabsmeddelelse Arzerra er blevet godkendt af de amerikanske sundhedsmyndigheder til brug i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL Godkendelsen...
August 25, 2016 00:01 ET | Source: Genmab A/S

Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine

Media Release The New England Journal of Medicine published data from the Phase III CASTOR study of daratumumab in relapsed or refractory multiple myeloma Study data initially presented at...
August 25, 2016 00:01 ET | Source: Genmab A/S

Data fra fase III studiet CASTOR med daratumumab publiceret i New England Journal of Medicine

Pressemeddelelse New England Journal of Medicine publicerer data fra fase III studiet CASTOR med daratumumab til behandling af recidiverende eller refraktær myelomatose Data fra studiet...
August 23, 2016 06:52 ET | Source: Genmab A/S

Genmab meddeler, at der er indsendt registreringsansøgning i Europa for daratumumab til behandling af recidiverende myelomatose

Selskabsmeddelelse Janssen har indsendt ansøgning til EMA om udvidelse af indikationsområdet for daratumumab til at omfatte recidiverende myelomatose Ansøgningen er baseret på data fra to...
August 23, 2016 06:52 ET | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma

Company Announcement Application to broaden label for daratumumab for relapsed multiple myeloma submitted to EMA by Janssen Submission based on data from two Phase III studies, CASTOR and...
August 18, 2016 14:03 ET | Source: Genmab A/S

Selskabsvedtægter for Genmab A/S

Selskabsvedtægter for Genmab A/S dateret den 17. august 2016 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
August 18, 2016 14:03 ET | Source: Genmab A/S

Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated August 17, 2016. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis...